BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 38429897)

  • 1. PI3K/AKT/mTOR inhibition in combination with doxorubicin is an effective therapy for leiomyosarcoma.
    Babichev Y; Kabaroff L; Datti A; Uehling D; Isaac M; Al-Awar R; Prakesch M; Sun RX; Boutros PC; Venier R; Dickson BC; Gladdy RA
    J Transl Med; 2016 Mar; 14():67. PubMed ID: 26952093
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elucidation of the Role of the Epigenetic Regulatory Mechanisms of PI3K/Akt/mTOR Signaling Pathway in Human Malignancies.
    Mohite R; Doshi G
    Curr Cancer Drug Targets; 2024; 24(3):231-244. PubMed ID: 37526459
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination effect of therapies targeting the PI3K- and AR-signaling pathways in prostate cancer.
    Yadav SS; Li J; Stockert JA; O'Connor J; Herzog B; Elaiho C; Galsky MD; Tewari AK; Yadav KK
    Oncotarget; 2016 Nov; 7(46):76181-76196. PubMed ID: 27783994
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EGFR and PI3K Signalling Pathways as Promising Targets on Circulating Tumour Cells from Patients with Metastatic Gastric Adenocarcinoma.
    Piper AK; Penney C; Holliday J; Tincknell G; Ma Y; Napaki S; Pantel K; Brungs D; Ranson M
    Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p38 Mitogen-Activated Protein Kinase Inhibition of Mesenchymal Transdifferentiated Tumor Cells in Head and Neck Squamous Cell Carcinoma.
    Federspiel J; Greier MDC; Ladányi A; Dudas J
    Biomedicines; 2023 Dec; 11(12):. PubMed ID: 38137525
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correction: Targeting EGFR/PI3K/AKT/mTOR signaling in lung and colon cancers: synthesis, antitumor evaluation of new 1,2,4-oxdiazoles tethered 1,2,3-triazoles.
    Ayoup MS; Shawki I; Abdel-Hamid H; Ghareeb DA; Masoud A; Harras MF; El-Atawy M; Alharbi NS; Ismail MMF
    RSC Adv; 2024 May; 14(25):17945. PubMed ID: 38841391
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The PI3K/Akt/mTORC signaling axis in head and neck squamous cell carcinoma: Possibilities for therapeutic interventions either as single agents or in combination with conventional therapies.
    Akbari Dilmaghani N; Safaroghli-Azar A; Pourbagheri-Sigaroodi A; Bashash D
    IUBMB Life; 2021 Apr; 73(4):618-642. PubMed ID: 33476088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting EGFR-PI3K-AKT-mTOR signaling enhances radiosensitivity in head and neck squamous cell carcinoma.
    Horn D; Hess J; Freier K; Hoffmann J; Freudlsperger C
    Expert Opin Ther Targets; 2015 Jun; 19(6):795-805. PubMed ID: 25652792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential modulation of PI3K/Akt/mTOR activity by EGFR inhibitors: A rationale for co-targeting EGFR and PI3K in cisplatin-resistant HNSCC.
    Liao J; Yang Z; Azarbarzin S; Cullen KJ; Dan H
    Head Neck; 2024 May; 46(5):1126-1135. PubMed ID: 38429897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simultaneously targeting ErbB family kinases and PI3K in HPV-positive head and neck squamous cell carcinoma.
    Yang Z; Liao J; Schumaker L; Carter-Cooper B; Lapidus RG; Fan X; Gaykalova DA; Mehra R; Cullen KJ; Dan H
    Oral Oncol; 2022 Aug; 131():105939. PubMed ID: 35667295
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A positive feedback loop involving EGFR/Akt/mTORC1 and IKK/NF-kB regulates head and neck squamous cell carcinoma proliferation.
    Li Z; Yang Z; Passaniti A; Lapidus RG; Liu X; Cullen KJ; Dan HC
    Oncotarget; 2016 May; 7(22):31892-906. PubMed ID: 26895469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MEK Inhibitor PD-0325901 Overcomes Resistance to PI3K/mTOR Inhibitor PF-5212384 and Potentiates Antitumor Effects in Human Head and Neck Squamous Cell Carcinoma.
    Mohan S; Vander Broek R; Shah S; Eytan DF; Pierce ML; Carlson SG; Coupar JF; Zhang J; Cheng H; Chen Z; Van Waes C
    Clin Cancer Res; 2015 Sep; 21(17):3946-56. PubMed ID: 25977343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ERK-dependent IL-6 autocrine signaling mediates adaptive resistance to pan-PI3K inhibitor BKM120 in head and neck squamous cell carcinoma.
    Yun MR; Choi HM; Kang HN; Lee Y; Joo HS; Kim DH; Kim HR; Hong MH; Yoon SO; Cho BC
    Oncogene; 2018 Jan; 37(3):377-388. PubMed ID: 28945228
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Anisuzzaman AS; Haque A; Wang D; Rahman MA; Zhang C; Chen Z; Chen ZG; Shin DM; Amin AR
    Mol Cancer Ther; 2017 Apr; 16(4):729-738. PubMed ID: 28119490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genomic Immune Evasion: Diagnostic and Therapeutic Opportunities in Head and Neck Squamous Cell Carcinomas.
    Kirtane K; St John M; Fuentes-Bayne H; Patel SP; Mardiros A; Xu H; Ng EW; Go WY; Wong DJ; Sunwoo JB; Welch JS
    J Clin Med; 2022 Dec; 11(24):. PubMed ID: 36555876
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.